Hospital Universitario Y Politecnico La Fe
Hospital Universitario Y Politecnico La Fe
Valencia, Spain15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06162572 | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-07 | NCT05512364 | |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-10-01 | NCT06016842 | |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Granuloma, Hemic and Lymphatic Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, astrocytoma (excluding glioblastoma), connective tissue neoplasm, epithelial neoplasm, glioblastoma, glioma, immune system disorder, immunoproliferative disorder, inflammatory myofibroblastic tumor, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, sarcoma, solitary fibrous tumor | Recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT04094610 | |
| Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-09-18 | NCT06191263 | |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoid syndrome, carcinoid tumor, carcinoma, cecum neuroendocrine tumor G1, enterochromaffin cell serotonin-producing pancreatic neuroendocrine tumor, epithelial neoplasm, ileal neuroendocrine tumor G1, intestinal neuroendocrine tumor G1, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, serotonin syndrome | Recruiting | Phase 3 | 2026-09-15 | NCT07087054 | |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, biliary tract cancer, biliary tract disorder, carcinoma, cholangiocarcinoma, epithelial neoplasm, gallbladder disorder, gallbladder neoplasm, neoplasm | Recruiting | Phase 3 | 2026-09-14 | NCT06282575 | |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | Neoplasms by Site, Thoracic Neoplasms, bronchial disorder, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-01 | NCT07185997 | |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-08-24 | NCT05020236 | |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Recruiting | Phase 3 | 2026-07-22 | NCT06072131 | |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Site, Neoplasms, Multiple Primary, Thoracic Neoplasms, autosomal dominant Parkinson disease 4, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, hereditary disease, hereditary neoplastic syndrome, lethal congenital contracture syndrome 2, lung disorder, lung neoplasm, malignant endocrine neoplasm, multiple endocrine neoplasia, multiple endocrine neoplasia type 2A, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, type 1 diabetes mellitus 12 | Recruiting | Phase 1 | 2026-07-22 | NCT05142189 | |
| PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Not stated | 2026-07-06 | NCT06321757 | |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 3 | 2026-02-06 | NCT06127407 | |
| Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites | Hypersensitivity, Immediate, Respiratory Hypersensitivity, Rhinitis, Allergic, asthma, bronchial disorder, immune system disorder, lung disorder, nasal disorder, obstructive lung disease, otorhinolaryngologic disease, respiratory system disorder, rhinitis | Recruiting | Phase 3 | 2025-05-13 | NCT04435990 | |
| Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock | Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Shock, Systemic Inflammatory Response Syndrome, toxic shock syndrome | Active, not recruiting | Phase 2 | 2023-04-11 | NCT04055909 |